Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

Universidad Autonoma de Nuevo Leon30 enrolled

Overview

The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Alopecia Areata

Interventions

Candida Albicans Antigen Injection

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of alopecia areata * SALT score of less than 50% extension * Has not received any topical or systemic treatment in the last month * Signed informed consent Exclusion Criteria: * Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features * Pregnancy or breast-feeding * Patients in medications that could cause hair loss as side-effects

Outcomes

Primary Outcomes

Treatment response

porcentage of hair growth determined by SALT score

Time frame: 5 months

Secondary Outcomes

Side effects

Side effects associated to the treatment